We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.
- Authors
Harper, Diane M; Franco, Eduardo L; Wheeler, Cosette M; Moscicki, Anna-Barbara; Romanowski, Barbara; Roteli-Martins, Cecilia M; Jenkins, David; Schuind, Anne; Costa Clemens, Sue Ann; Dubin, Gary; HPV Vaccine Study group
- Abstract
Effective vaccination against HPV 16 and HPV 18 to prevent cervical cancer will require a high level of sustained protection against infection and precancerous lesions. Our aim was to assess the long-term efficacy, immunogenicity, and safety of a bivalent HPV-16/18 L1 virus-like particle AS04 vaccine against incident and persistent infection with HPV 16 and HPV 18 and their associated cytological and histological outcomes.
- Publication
Lancet (London, England), 2006, Vol 367, Issue 9518, p1247
- ISSN
1474-547X
- Publication type
Journal Article
- DOI
10.1016/S0140-6736(06)68439-0